NCT06367062

Brief Summary

International large-scale clinical studies have found that prolonged or repeated exposure to general anesthesia drugs in infancy and early childhood can lead to an increased risk of long-term neurodevelopmental abnormalities in children. The study of neurodevelopmental toxicity of general anesthesia drugs is of great social significance. We have established a rhesus monkey model to study the neurodevelopmental toxicity of general anesthetic drugs, the first time to make a preliminary exploration of the mechanism of myelin developmental toxicity of general anesthetic drugs. Several studies using magnetic resonance scanning found a positive correlation between the number of anesthesia exposures and the maturity of distant brain white matter development in juvenile non-human primates. Clinical evidence for myelin developmental toxicity induced by general anesthetic drugs needs to be collected by conducting multicenter and large-sample clinical studies. Earlier studies have either had low sample sizes, which do not allow for better control of confounding factors; or the study population has been limited to specific disease populations, and the results cannot be extrapolated to normal children. In view of this, based on the applicant's earlier study, this project proposes to recruit children who underwent general anesthesia surgery between 0-3 years of age and are now 12-15 years old; children who did not experience surgery between 0-3 years of age were matched by age-sex to serve as a control group. MRI will be used to assess their brain white matter development, to explore the correlation between anesthesia and anesthesia-related factors and brain white matter development and related neurobehavioral development, and to clarify the effects of anesthesia and surgery on children's brain white matter and related neuropsychological development.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
210

participants targeted

Target at P75+ for all trials

Timeline
7mo left

Started May 2024

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
May 2024Dec 2026

First Submitted

Initial submission to the registry

April 10, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 16, 2024

Completed
15 days until next milestone

Study Start

First participant enrolled

May 1, 2024

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

April 16, 2024

Status Verified

December 1, 2023

Enrollment Period

2.6 years

First QC Date

April 10, 2024

Last Update Submit

April 15, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • MRI-based assessment of brain development

    Magnetic resonance scanning of T1-weighted images, T2-weighted images, and diffusion tensor imaging (DTI) of both cerebral hemispheres, looking at whole-brain white matter volume as a percentage of total intracranial volume

    one time, through study completion, an average of 3 month

Study Arms (3)

Multiple anesthesia group

Children who underwent more than one general anesthesia procedure between the ages of 0-3 years.

Other: MRI

Single anesthesia group

Children who underwent only one general anesthesia procedure between the ages of 0-3 years.

Other: MRI

Control group

Children who underwent no general anesthesia procedure between the ages of 0-3 years.

Other: MRI

Interventions

MRIOTHER

MRI is used to assess of brain development.

Control groupMultiple anesthesia groupSingle anesthesia group

Eligibility Criteria

Age12 Years - 15 Years
Sexall
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Age between 12-15 years.Past history doesn't lead to abnormal brain development.

You may qualify if:

  • Currently between 12 and 15 years of age

You may not qualify if:

  • Surgical complications such as acute infectious diseases, systemic diseases
  • Abnormal findings on cerebral white matter and/or neurobehavioral assessment
  • History of neonatal ischemic-hypoxic encephalopathy, bilirubin encephalopathy
  • Genetic or chromosomal disorders, neurological disorders (including epilepsy, congenital disorders), or a history of craniocerebral trauma, infectious diseases of the central nervous system, febrile convulsions, congenital heart disease, oncological diseases, and blood disorders
  • Autism, attention deficit hyperactivity disorder, or those who have received behavioral therapy and intervention.
  • Children with organic damage to the nervous system
  • Cardiovascular surgery, neurosurgery or intraoperative hemodynamic instability.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 10, 2024

First Posted

April 16, 2024

Study Start

May 1, 2024

Primary Completion (Estimated)

November 30, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

April 16, 2024

Record last verified: 2023-12